Pfizer Launches Free Medicines Program For Newly Unemployed Americans
Pfizer Inc will launch an innovative program to help eligible unemployed Americans and their families who have lost their health insurance maintain access to their Pfizer medicines for free. The inspiration for the new program, called MAINTAIN™ (Medicines Assistance for Those who Are in Need), was generated by Pfizer employees who were witnessing friends, family and neighbors struggle to make ends meet after losing their jobs.
Read more ...
Qlaira® - innovative estradiol-based oral contraceptive available in Europe
Bayer Schering Pharma AG, Germany, is starting the European roll-out of its new oral contraceptive Qlaira® (estradiol valerate/dienogest). From May 15, 2009, Qlaira® will be available in several European countries, including Germany. More European countries will follow from autumn 2009 onwards.
Read more ...
Boehringer Ingelheim and DeveloGen AG announce agreement
Boehringer Ingelheim and DeveloGen AG, have announced the signing of an asset sale and purchase and collaboration agreement in the field of diabetes, obesity, the metabolic syndrome and other insulin resistance associated disorders.
Read more ...
Roche provides additional donation of 5.65 million packs of Tamiflu to WHO
Roche has announced a new donation to the World Health Organization (WHO) of 5.65 million courses of treatment of the antiviral drug Tamiflu (oseltamivir). This donation includes:
Replenishment of the Regional Stockpile of 2 million treatment courses of Tamiflu to be held by the WHO and used to address regional outbreaks,
AstraZeneca Announces Top Line Results From Pivotal Phase III Study for BRILINTA
AstraZeneca has announced top line results from the phase III trial, PLATO (A Study of Platelet Inhibition and Patient Outcomes), which demonstrate that BRILINTA (ticagrelor), the investigational oral antiplatelet treatment for acute coronary syndromes (ACS), has achieved a statistically significant primary efficacy endpoint versus clopidogrel, in the prevention of cardiovascular (CV) events in patients with ACS.
Read more ...
Novo Nordisk reaches settlements regarding Oil-for-Food activities
Novo Nordisk announced today that it has entered into a consent agreement with the US Securities and Exchange Commission (SEC) and a deferred prosecution agreement with the US Department of Justice (DOJ) resolving their investigations of the company's sales to Iraq during 2000 to 2003 under the UN's Oil-for-Food programme.
Read more ...